Current Status on Treatments and Clinical Trials for COVID-19 (Preprint)

2020 ◽  
Author(s):  
Guosheng Yin ◽  
Chenyang Zhang ◽  
Huaqing Jin
Keyword(s):  
Clinical Trials ◽  
Phase Ii ◽  
Developmental Process ◽  
Current Situation ◽  
Current Status ◽  
The Novel ◽  
Fast Speed ◽  
Death Toll ◽  
Number Of Patients ◽  
Novel Coronavirus

UNSTRUCTURED With the worldwide rapidly growing number of patients infected with the novel coronavirus (COVID-19), the death toll has also been climbing up at a fast speed. There is an urgent need to search for cures for COVID-19 patients. A large number of clinical trials have been launched to test some existing or new antiviral therapeutics and vaccines. In contrast to starting from the scratch, many trials are initiated directly in phase II or III with the hope to expedite the developmental process. We summarize the information on the registered trials for the top ten COVID-19 drugs, and give an overview on the current situation and trend of treatments and clinical trials. In particular, we review those trials that have already been finished and discuss lessons that can be learned from them.

scholarly journals The impact of COVID-19 pandemic on the treatment of acute appendicitis in China

2021 ◽  
Author(s):  
ZhiXue Zheng ◽  
Jing Tao Bi ◽  
Ya Qi Liu ◽  
Xuan Cai
Keyword(s):  
Acute Appendicitis ◽  
White Blood Cells ◽  
Onset Time ◽  
The Novel ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Number Of Patients ◽  
Hospital Visits ◽  
Novel Coronavirus ◽  
The Impact

Abstract Objective This research aims to analyze the impact of the novel coronavirus pandemic on the hospital visits of patients with acute appendicitis. Methods The retrospective analysis was designed to look at the treatment of acute appendicitis in the Department of General Surgery in Beijing Jishuitan Hospital before and during the COVID-19 pandemic (2019–2020). Data was analyzed by the numbers of patients, sex, age, onset time, fever or not, laboratory examination, imaging test, and treatment. And we analyzed the differences between the “pre-COVID group” and “during-COVID group”. Results Compared with the year 2019, the number of acute appendicitis patients has diminished substantially during the COVID-19 pandemic (2020), but the number elevated with the control of the pandemic. Even if we did not find the differences of the treatment before and during the pandemic (P = 0.932), the onset time to emergency was significantly longer (P < 0.001), and more patients had showed fever (P < 0.001) during the COVID-19 pandemic. And the total number of white blood cells and C reactive protein level were significantly higher in 2020 than those in 2019 (P = 0.006, 0.003). And the same result was found in patients with appendiceal fecalith (P = 0.047). Conclusion During the pandemic of the new coronavirus pneumonia, the number of patients with acute appendix treatment dropped significantly, mainly because it took longer than before, and the condition was more severe. It can be seen that the new coronary pneumonia has a great impact on the patients’ medical treatment behavior, and the active prevention and treatment of the new coronavirus pneumonia is currently an important and urgent issue.

scholarly journals Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge

2020 ◽  
Vol 120 (06) ◽  
pp. 949-956 ◽  
Author(s):  
Francesco Violi ◽  
Daniele Pastori ◽  
Roberto Cangemi ◽  
Pasquale Pignatelli ◽  
Lorenzo Loffredo
Keyword(s):  
Multiorgan Failure ◽  
Laboratory Data ◽  
Clinical Severity ◽  
The Novel ◽  
Antithrombotic Treatment ◽  
Clotting System ◽  
Thrombotic Risk ◽  
Number Of Patients ◽  
Coronary Ischemia ◽  
Novel Coronavirus

AbstractThe novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment.

scholarly journals POTENTIAL THERAPIES FOR TREATMENT OF COVID-19

2020 ◽  
Vol 7 (1) ◽  
pp. 062-071
Author(s):  
Beatriz Gasser ◽  
Ricardo Andres Ramirez Uscategui
Keyword(s):  
Clinical Trials ◽  
Distress Syndrome ◽  
Multiple Organ ◽  
The Novel ◽  
Controlled Clinical Trials ◽  
Interferon Β ◽  
The World ◽  
Novel Coronavirus ◽  
Time Point

Since discovery of the novel coronavirus (SARS-CoV-2) in December of 2019, this viral pneumonia originated in Wuhan, China quickly spread around the world. This new disease, called COVID-19 can cause Acute Respiratory Distress Syndrome (ARDS) due to an uncontrolled inflammatory response like sepsis, that leads to multiple organ failure and even death. Several pharmacotherapeutics alternatives are being tested over the world, looking for most diverse drugs that might be able to fight the infection. The objective of this paper is to review the main pharmacotherapeutics techniques development, as remdesivir, chloroquine/hydroxychloroquine, lopinavir plus ritonavir, interferon-β, ivermectin, anticoagulants, convalescent plasma and vaccine, currently undergoing clinical trials in order to evaluate its effectiveness and safety to combat the COVID-19, presenting their characteristics, possible adverse effects and main scientific findings of its potential action. In conclusion, some therapies presented promising in-vitro results or in the treatment of some patients, nonetheless, multicentric blinded placebo controlled clinical trials are necessary to determine their effectiveness, safety, dosage, and best time point of treatment.

scholarly journals First month of the epidemic caused by COVID-19 in Italy: current status and real-time outbreak development forecast

2020 ◽  
Vol 5 (1) ◽  
Author(s):  
Rosario Megna
Keyword(s):  
Real Time ◽  
Forecast Model ◽  
Current Status ◽  
Logistic Distribution ◽  
Infected People ◽  
The North ◽  
Number Of Patients ◽  
Heavy Burden ◽  
Novel Coronavirus ◽  
Health Organization

Abstract Background The first outbreak of COVID-19 in Italy occurred during the second half of February 2020 in some areas in the North of the country. Due to the high contagiousness of the infection, further spread by asymptomatic people, Italy has become in a few weeks the country with the greatest number of infected people in the world. The large number of severe cases among infected people in Italy led to the hospitalization of thousands of patients, with a heavy burden on the National Health Service. Methods We analyzed data provided daily by Italian Authorities for the period from 24 February 2020 to 30 March 2020. Considering such information, we developed a forecast model in real-time, based on the cumulative log-logistic distribution. Results A total of 101,739 infected individuals were confirmed until 30 March 2020, of which 14,620 recovered or discharged, and 11,591 deaths. Until the same date patients quarantined at home were 43,752, whereas hospitalized patients were 31,776, of which 3981 in intensive care. The active cases (i.e. the number of patients not yet recovered until that date) were 75,528. The forecast model estimated a number of infected persons for Italy of 234,000 about, and a duration of the epidemic of approximately 4 months. Conclusions One month after the first outbreaks there seemed to be the first signs of a decrease in the number of infections, showing that we could be now facing the descending phase of the epidemic. The forecast obtained thanks to our model could be used by decision-makers to implement coordinative and collaborative efforts in order to control the epidemic. The pandemic due to novel Coronavirus must be a warning for all countries worldwide, regarding a rapid and complete dissemination of information, surveillance, health organization, and cooperation among the states.

scholarly journals Bayesian Adaptive Randomized Trial Design for Patients With Recurrent Glioblastoma

2012 ◽  
Vol 30 (26) ◽  
pp. 3258-3263 ◽  
Author(s):  
Lorenzo Trippa ◽  
Eudocia Q. Lee ◽  
Patrick Y. Wen ◽  
Tracy T. Batchelor ◽  
Timothy Cloughesy ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase Ii ◽  
Survival Data ◽  
Trial Design ◽  
Statistical Power ◽  
Power Level ◽  
Recurrent Glioblastoma ◽  
Phase Ii Trials ◽  
Number Of Patients ◽  
Short Time

Purpose To evaluate whether the use of Bayesian adaptive randomized (AR) designs in clinical trials for glioblastoma is feasible and would allow for more efficient trials. Patients and Methods We generated an adaptive randomization procedure that was retrospectively applied to primary patient data from four separate phase II clinical trials in patients with recurrent glioblastoma. We then compared AR designs with more conventional trial designs by using realistic hypothetical scenarios consistent with survival data reported in the literature. Our primary end point was the number of patients needed to achieve a desired statistical power. Results If our phase II trials had been a single, multiarm trial using AR design, 30 fewer patients would have been needed compared with a multiarm balanced randomized (BR) design to attain the same power level. More generally, Bayesian AR trial design for patients with glioblastoma would result in trials with fewer overall patients with no loss in statistical power and in more patients being randomly assigned to effective treatment arms. For a 140-patient trial with a control arm, two ineffective arms, and one effective arm with a hazard ratio of 0.6, a median of 47 patients would be randomly assigned to the effective arm compared with 35 in a BR trial design. Conclusion Given the desire for control arms in phase II trials, an increasing number of experimental therapeutics, and a relatively short time for events, Bayesian AR designs are attractive for clinical trials in glioblastoma.

Sign in / Sign up

Export Citation Format

Share Document